Key Drivers
- High liquidity
- Persistent losses
- Negative FCF
AIAI Summary
Centessa has shifted from a speculative, pre‑revenue biotech to a liquidity‑backed development platform where partner milestone receipts and invested assets materially extend optionality, but that optionality only matters if cash/investments are converted and R&D spend translates into positive orexin clinical readouts. Actionable triggers to watch: upcoming OX2R readouts, conversion of invested assets to cash (runway math), and continued insider/institutional selling — any missed catalyst or stalled cash conversion likely forces dilutive financing and large downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High liquidity
- •Persistent losses
- •Negative FCF
Centessa shows strong liquidity and low leverage but no revenue, steep and persistent operating losses, sharply declining cash with negative free cash flow, and a valuation that looks speculative pending revenue/R&D success.
Price Behavior
Key Price Behavior Insights:
- •Higher highs/lows
- •Recent pullback
- •Moderate volatility
Over the last month the stock rallied roughly 10% to $27.08 with higher highs/lows, facing near-term resistance at $28.95–$29.00 and support at $24.50–$25.50 while a pullback from the 2026-03-17 peak suggests short-term consolidation and profit-taking risk.
Sharp peak near $28.95 on 2026-03-17 followed by a short-term pullback
Sentiment & News
Key News Insights:
- •Orexin momentum
- •Milestone payment
- •Significant selling
Centessa shows advancing orexin clinical momentum (ORX750 Phase II update, ORX489 milestone and registrational starts) alongside material institutional and insider share sales signaling notable shareholder liquidation.
Clinical progress could re-rate the stock, but substantial institutional and insider selling may limit near-term upside and raise volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings